Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Novel HER-2 Positive Therapies Provide Diversified Treatment Options

ResearchMoz.us include new market research report "Breast Cancer Therapeutics in Asia-Pacific Markets to 2020" to its huge collection of research reports. Get full report with TOC at http://www.researchmoz.us/breast-cancer-therapeutics-in-asia-pacific-markets-to-2020-novel-her-2-positive-therapies-provide-diversified-treatment-options-report.html.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friendRepost This
ResearchMoz

ResearchMOZ

Australia, China and Japan was worth $1.5 billion in 2013 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 7.6% to $2.5 billion by 2020.

Albany,New York (PRWEB) May 08, 2014

Researchmoz presents this most up-to-date research on "Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 – Novel HER-2 Positive Therapies Provide Diversified Treatment Options". The report focuses primarily on quantitative market metrics in order to characterize the growth and evolution of the Remote Patient Monitoring Market.

Research, the leading business intelligence provider, has released its latest research: ‘Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 – Novel HER-2 Positive Therapies Provide Diversified Treatment Options’, which provides in-depth analysis of breast cancer market within the Asia-Pacific (APAC) covering the four countries of Australia, China, India and Japan. The report provides an estimation of market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis. The breast cancer therapeutics market in the four Asia-Pacific (APAC) countries of India, Australia, China and Japan was worth $1.5 billion in 2013 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 7.6% to $2.5 billion by 2020. Japan had the largest market in 2013 with a value of $872m, or a share of 58%, followed by China with $320m or 21%, and Australia with $234m or 16%. India had the lowest market share and value at 5% and $81m, but is expected to witness the fastest growth over the forecast period with a CAGR of 13.8%, compared to Australia at 7.8% and China and Japan both at 7.7%.

Get detail research reports with TOC at http://www.researchmoz.us/breast-cancer-therapeutics-in-asia-pacific-markets-to-2020-novel-her-2-positive-therapies-provide-diversified-treatment-options-report.html.

Scope
The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in the breast cancer therapeutics in the four APAC markets of Australia, China, India and Japan.

The report includes:

  • Disease overview, as well as treatment algorithms and treatment usage patterns
  • Market size and forecast for the APAC breast cancer market from 2013 to 2020
  • Major marketed products in the APAC region along with a heat map of product performance
  • In-depth pipeline analysis for global pipeline in breast cancer drugs along with clinical trial failure rate analysis
  • Key drivers and restraints that have had and are expected to have a significant impact upon the market
  • Key licensing and co-development agreements that could have impact on growth trends

Market Research Related Reports :

Competitor Analysis: Biosimilar and Biosuperior Therapeutic Antibodies 2014 - http://www.researchmoz.us/competitor-analysis-biosimilar-and-biosuperior-therapeutic-antibodies-2014-report.html

The report lists specifically for each target the branded products with their 2013 sales and up-side indications in development, as well as follower, biosuperior and biosimilar antibody drug candidates in development.Marketed antibodies are attractive for companies to create next generation variants and biosimilar copies because they represent clinically and commercially validated products. New technologies such as Fc engineering, polyclonal mixtures, antibody drug conjugates or bispecific molecules as well as the expiration of patents stimulate the discovery and development of biosimilar and biosuperior/biobetter molecules.Total sales of recombinant therapeutic monoclonal antibodies originating from companies located in regulated markets reached US$ 75.7 bln in the year 2013. Cumulated 2013 sales of branded therapeutic antibodies approaching patent expiry and, therefore, target of biosimilar substitution, reached US$ 58.6 bln.

PharmaSphere: Emerging Biotech Investment Report - Strategic Trends in Private Equity and Venture Capital Funding - http://www.researchmoz.us/pharmasphere-emerging-biotech-investment-report-strategic-trends-in-private-equity-and-venture-capital-funding-report.html

"PharmaSphere: Emerging Biotech Investment Report Strategic Trends in Private Equity and Venture Capital Funding" report provides in-depth analysis of the current trends and factors shaping the private equity and venture capital segments of the financial industry, bearing in mind that these are expected to have significant impact on the future of emerging biotechnology companies in the US and globally. Furthermore, the report identifies regions of the world that are attracting more investments in healthcare and discusses the various factors responsible for this trend. In addition, the report provides detailed profiles of 12 leading private equity firms, 15 top venture capital firms, and 15 US-based emerging biotechnology companies that completed initial public offerings in 2013.Throughout the report, analysts provide you with expert insight, expanding on each observation, strategy, and trend discussed, with the aim of providing you with the tools needed for making informed business decisions in the rapidly changing global investment landscape.

For category wise research reports visit at http://www.researchmoz.us/category.html.

Reasons to Buy

The report will enhance your decision-making capability by allowing you to:

  • Align your product portfolio to the markets with high growth potential
  • Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
  • Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the breast cancer drugs market
  • Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships

Browse all latest market research reports at http://www.researchmoz.us/latest-report.html.

About Us:
ResearchMoz is the one stop online destination to find and buy market research reports. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets.

Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. We provide the market context, competitor insight and future trends needed for strategic planning.

For More Information Contact:
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-997-4948
Web: http://www.researchmoz.us/
Email: sales(at)researchmoz(dot)us
Blog: http://medicaldevicesmarket.blogspot.com